← Back to Patent Explorer
US4151301A Expired / Lapsed US ⏱️ 0.0 years remaining

Orally administered composition containing organic amine-organic acid addition salt for reducing excessive secretion of sebum on human skin and scalp

Assignee: L'Oréal SA
•
Filing: 1976-10-29
•
Granted: 1979-04-24
•
Expires: 1996-10-29
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention is directed to compositions which can be orally administered to humans suffering from a condition characterized by excessive secretion of sebum from the scalp or skin, for the purpose of improving that condition. The compositions include a solid ingestible carrier admixed with certain non-toxic active compounds of the formula <IMAGE> WHICH ARE MORE FULLY AND SPECIFICALLY DESCRIBED BELOW.

Inventors

  • 👤 Gregoire Kalopissis

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-31 03:06
CPC Classifications
C; C07; C07D; C07D333/00; C07D333/02; C07D333/04; C07D333/06; C07D333/14; C07D333/18; A; A61; A61K; A61K8/00; A61K8/18; A61K8/30; A61K8/40; A61K8/44; A61K8/447; A61K8/46; A61Q; A61Q19/00; A61Q19/008; A61Q5/00; A61Q5/008; C07C; C07C323/00; C07C323/23; C07C323/24; C07C323/25; C07C323/39; C07C323/43; C07C323/44; C07C323/50; C07C323/51; C07C323/52; C07D213/00; C07D213/02; C07D213/04; C07D213/60; C07D213/78; C07D213/81; C07D213/82; A61K2800/00; A61K2800/80; A61K2800/92; A61Q5/02; A61Q5/06; A61Q5/065; Y; Y10; Y10S; Y10S424/00; Y10S424/04

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 289 words
A composition for oral administration to a human having a scalp or skin characterized by an excessive secretion of sebum to improve the condition thereof by reducing said excessive secretion of sebum comprising in admixture with a solid ingestible carrier from 0.75 to 20 weight percent of a non-toxic active compound selected from the group consisting of: 5-amino-3-thia hexanedioate of 2-benzylthio-ethylammonium, 5-acetamido-3-thia-hexanedioate of di-(2-benzyl-thioethylammonium), 5-amino-3-thia hexanedioate of 2-(3-alanylthio) ethylammonium, 5-amino-3-thia hexanedioate of 2-methylthioethylammonium, 5-amino-3-thia hexanedioate of 3-benzylthiopropylammonium, 2-amino-4-thia heptanedioate of 2-benzylthioethylammonium, 5-amino-3-thia hexanedioate of 2-(2,2-dimethoxyethylthio)-ethylammonium, 2-acetamido-3-benzylthio-propionate of 2-methylthioethylammonium, 5-benzamido-3-thia-hexanedioate of di(2-benzylthioethylammonium), 5-p-toluenesulfonamido-3-thia-hexanedioate of di(2-benzylthioethylammonium), 5-p-acetamidobenzenesulfonamido-3-thia-hexanedioate of di-(2-benzylthioethylammonium), 5-p-acetamidobenzamido-3-thia-hexanedioate of di(2-benzylthioethylammonium), 2-acetamido-4-thia-heptanedioate of di(2-methylthio-ethylammonium), 2-amino-4-thia decanedioate of 2-benzylthioethylammonium, 5-amino-3-thia hexanedioate of 2-benzylthiopropylammonium, 5-amino-3-thia hexanedioate of 2-benzylthio-2-methylpropylammonium, 5-amino-3-thia hexanedioate of 2-phenylthioethylammonium, 5-amino-3-thia hexanedioate of 2-t-butylthioethylammonium, 5-amino-3-thia hexanedioate of 2-tritylthioethylammonium, 5-amino-3-thia hexanedioate of 2-(2-butenylthio) ethylammonium, 5-amino-3-thia hexanedioate of 2-(2-hydroxyethylthio)ethylammonium, 5-amino-3-thia hexanedioate of 2-(2,3-dihydroxypropylthio) ethylammonium, 3-benzylthio-2-phenylacetamido propionate of 2-methylthioethylammonium, 2-acetamido-3-tritylthiopropionate of 2-methylthioethylammonium, 2-acetamido-3-benzhydrylthio propionate of 2-methylthioethylammonium, 5-amino-3-thia hexanedioate of 6-methanesulfonamido-6-ethoxy carbonyl-4-thia hexylammonium, 2-acetamido-4-thia-nonanedioate of 2,2'-thio bis (ethylammonium), di-(β-benzylthioethylammonium) 5-p-acetamido-3-thiahexanedioate, 5-amino-3-thia acid hexanedioate of 2-octadecylthio ethylammonium, 2-amino-4-thia heptanedioate of 2-undecenylthio ethylammonium, 2-amino-4-thia nonanedioate of 2-(3-hydroxypropylthio) ethylammonium, di-(5-amino-3-thia hexanedioate) of 3-thia-1,6-hexanediammonium, 2-amino-4-thia octanedioate of 2-(β-ureido ethylthio)ethylammonium, 5-amino-3-thia hexanedioate of 2-(3-methanesulfonamido propylthio) ethylammonium, 5-amino-3-thia hexanedioate of 2-(p-phenylbenzylthio) ethylammonium, 5-tetradecanamido-3-thia hexanedioate of di(2-β-hydroxyethyl thio ethylammonium), 2-crotonamido-4-thia heptanedioate of di(2-tertiobutylthio ethylammonium), 2-butanesulfonamido-4-thia octanedioate of 2,2'-(2,3-dihydroxy-1,4-butanediyl dithio) diethylammonium, 2-formamido-3-(propyn-2-ylthio) propionate of 3-(1-naphthyl thio) propylammonium, 3-methylthio-2-trifluoroacetamido propionate of 2-oleylthio ethylammonium, 2-o-chlorobenzylthiomethyl-3-aza-4-oxo heptanedioate of 5,5'-sulfonyl bis (3-thia pentylammonium), 2-acetamido-3-p-methylthiophenylthio propionate of 2-(2,4,6-trimethyl benzylthio) ethylammonium, 5-amino-3-thia hexanedioate of 2-(3,4-dichlorobenzylthio) ethylammonium, 2-butyramido-3-isopropylthio propionate of 2-(2,6-dichlorobenzylthio) ethylammonium, 2-acetamido-3-(3-alanylthio) propionate of 2-m-fluorobenzylthio ethylammonium, 6-amino-3-thia heptanedioate of 2-p-dimethylaminobenzylthio ethylammonium, 2-hexanamido-di-(p-methoxyphenyl)-3-methylthio propionate of 2-(2,3-dihydroxy propylthio) ethylammonium, 5-amino-3-thia hexanedioate of 2-(o-chlorobenzylthio) ethylammonium, 5-amino-3-thia hexanedioate of 2-(p-bromobenzylthio) ethylammonium, 5-acetamido-3-thia hexanedioate of di-2-(2,4-dichlorobenzylthio) ethylammonium, and 2-acetamido-3-p-fluorobenzylthio propionate of 2-hexadecylthio ethylammonium.
Claim 2
Dependent Claim 289 words
A composition for oral administration to a human having a scalp or skin characterized by an excessive secretion of sebum to improve the condition thereof by reducing said excessive secretion of sebum comprising in admixture with a solid ingestible carrier from 0.75 to 20 weight percent of a non-toxic active compound selected from the group consisting of: 5-amino-3-thia hexanedioate of 2-benzylthio-ethylammonium, 5-acetamido-3-thia-hexanedioate of di-(2-benzyl-thioethylammonium), 5-amino-3-thia hexanedioate of 2-(3-alanylthio) ethylammonium, 5-amino-3-thia hexanedioate of 2-methylthioethylammonium, 5-amino-3-thia hexanedioate of 3-benzylthiopropylammonium, 2-amino-4-thia heptanedioate of 2-benzylthioethylammonium, 5-amino-3-thia hexanedioate of 2-(2,2-dimethoxyethylthio)-ethylammonium, 2-acetamido-3-benzylthio-propionate of 2-methylthioethylammonium, 5-benzamido-3-thia-hexanedioate of di(2-benzylthioethylammonium), 5-p-toluenesulfonamido-3-thia-hexanedioate of di(2-benzylthioethylammonium), 5-p-acetamidobenzenesulfonamido-3-thia-hexanedioate of di-(2-benzylthioethylammonium), 5-p-acetamidobenzamido-3-thia-hexanedioate of di(2-benzylthioethylammonium), 2-acetamido-4-thia-heptanedioate of di(2-methylthio-ethylammonium), 2-amino-4-thia decanedioate of 2-benzylthioethylammonium, 5-amino-3-thia hexanedioate of 2-benzylthiopropylammonium, 5-amino-3-thia hexanedioate of 2-benzylthio-2-methylpropylammonium, 5-amino-3-thia hexanedioate of 2-phenylthioethylammonium, 5-amino-3-thia hexanedioate of 2-t-butylthioethylammonium, 5-amino-3-thia hexanedioate of 2-tritylthioethylammonium, 5-amino-3-thia hexanedioate of 2-(2-butenylthio) ethylammonium, 5-amino-3-thia hexanedioate of 2-(2-hydroxyethylthio)ethylammonium, 5-amino-3-thia hexanedioate of 2-(2,3-dihydroxypropylthio) ethylammonium, 3-benzylthio-2-phenylacetamido propionate of 2-methylthioethylammonium, 2-acetamido-3-tritylthiopropionate of 2-methylthioethylammonium, 2-acetamido-3-benzhydrylthio propionate of 2-methylthioethylammonium, 5-amino-3-thia hexanedioate of 6-methanesulfonamido-6-ethoxy carbonyl-4-thia hexylammonium, 2-acetamido-4-thia-nonanedioate of 2,2'-thio bis (ethylammonium), di-(β-benzylthioethylammonium) 5-p-acetamido-3-thiahexanedioate, 5-amino-3-thia acid hexanedioate of 2-octadecylthio ethylammonium, 2-amino-4-thia heptanedioate of 2-undecenylthio ethylammonium, 2-amino-4-thia nonanedioate of 2-(3-hydroxypropylthio) ethylammonium, di-(5-amino-3-thia hexanedioate) of 3-thia-1,6-hexanediammonium, 2-amino-4-thia octanedioate of 2-(β-ureido ethylthio)ethylammonium, 5-amino-3-thia hexanedioate of 2-(3-methanesulfonamido propylthio) ethylammonium, 5-amino-3-thia hexanedioate of 2-(p-phenylbenzylthio) ethylammonium, 5-tetradecanamido-3-thia hexanedioate of di(2-β-hydroxyethyl thio ethylammonium), 2-crotonamido-4-thia heptanedioate of di(2-tertiobutylthio ethylammonium), 2-butanesulfonamido-4-thia octanedioate of 2,2'-(2,3-dihydroxy-1,4-butanediyl dithio) diethylammonium, 2-formamido-3-(propyn-2-ylthio) propionate of 3-(1-naphthyl thio) propylammonium, 3-methylthio-2-trifluoroacetamido propionate of 2-oleylthio ethylammonium, 2-o-chlorobenzylthiomethyl-3-aza-4-oxo heptanedioate of 5,5'-sulfonyl bis (3-thia pentylammonium), 2-acetamido-3-p-methylthiophenylthio propionate of 2-(2,4,6-trimethyl benzylthio) ethylammonium, 5-amino-3-thia hexanedioate of 2-(3,4-dichlorobenzylthio) ethylammonium, 2-butyramido-3-isopropylthio propionate of 2-(2,6-dichlorobenzylthio) ethylammonium, 2-acetamido-3-(3-alanylthio) propionate of 2-m-fluorobenzylthio ethylammonium, 6-amino-3-thia heptanedioate of 2-p-dimethylaminobenzylthio ethylammonium, 2-hexanamido-di-(p-methoxyphenyl)-3-methylthio propionate of 2-(2,3-dihydroxy propylthio) ethylammonium, 5-amino-3-thia hexanedioate of 2-(o-chlorobenzylthio) ethylammonium, 5-amino-3-thia hexanedioate of 2-(p-bromobenzylthio) ethylammonium, 5-acetamido-3-thia hexanedioate of di-2-(2,4-dichlorobenzylthio) ethylammonium, and 2-acetamido-3-p-fluorobenzylthio propionate of 2-hexadecylthio ethylammonium.
Claim 3
Dependent Claim 14 words
The composition of claim 1 wherein the active compound is: 5-amino-3-thia hexanedioate of 2-benzylthio-ethylammonium.
Claim 4
Dependent Claim 19 words
The composition of claim 1 in dosage form which contains 10-75 mg of said active compound per unit dose.
Claim 5
Dependent Claim 46 words
A method for treating the scalp and skin, characterized by an excessive secretion of sebum, to improve the condition thereof by reducing said excessive secretion of sebum comprising orally administering to a human being having a scalp or skin so characterized the composition of claim 1.
Claim 6
Dependent Claim 36 words
The method of claim 4 wherein said composition is administered at a rate of about 1-5 mg/kg/day based on the weight of the human being for a time sufficient to reduce said excessive secretion of sebum.
Claim 7
Dependent Claim 17 words
The method of claim 5 wherein said composition is administered during a period of about 15 days.

References Cited (Backward Citations)

FR1085513A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1982-04-23 1982-10-23 1983-04-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1986-04-23 1986-10-23 1987-04-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1990-04-23 1990-10-23 1991-04-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag